Advanced Fibrosis Detection for MASLD in Primary Care
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Primary Care
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Patients Inclusion Criteria: * Patients with a diagnosis code for MASLD * Type 2 diabetes mellitus will Exclusion Criteria: * All patients with cirrhosis, complications of cirrhosis (e.g. portal hypertension, hepatic encephalopathy), hepatocellular carcinoma, or previous liver transplant will be excluded. * pregnant women. Clinicians Clinicians will also be study participants, as we will be surveying them for feedback on the MASLD fibrosis risk assessment intervention. The MUSC primary care network at last count employed 122 clinicians across the 27 primary care practices. Inclusion criteria: 1\. All physicians, physician assistants, and nurse practitioners delivering primary care during the intervention phase of the study. Exclusion criteria: None
About the study
This proposal evaluates the implementation of a novel, non-interruptive, electronic health record alert for metabolic dysfunction-associated steatotic liver disease (MASLD) fibrosis risk assessment in primary care patients with MASLD using a stepped wedge, cluster randomized design. This work will generate generalizable data to dramatically enhance MASLD management in primary care.
What is being tested
- EHR alert (other)
Sponsor: Medical University of South Carolina · Participants: 225 · Started: Mar 16, 2026
Contact the study team
- Andrew Schreiner, MD, MSCR · Phone: (843) 876-0888
Official record on ClinicalTrials.gov — NCT07159386
Locations in the U.S.
| South Carolina | Medical University of South Carolina, Charleston |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.